Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standard fluid management-Thomas Jefferson University-aneurysmal subarachnoid hemorrhage refers to the control arm protocol used in the HS3 (Hypertonic Saline in Aneurysmal SAH) Phase II clinical trial. This protocol represents the conventional isotonic fluid therapy (typically 0.9% sodium chloride) administered to patients following an aneurysmal subarachnoid hemorrhage (aSAH) to maintain euvolemia and prevent medical complications such as hyponatremia. In the context of the HS3 trial, this standard-of-care approach was used as a comparator to evaluate the safety and efficacy of 3% hypertonic saline in preventing cerebral vasospasm and improving clinical outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Standard fluid management-Thomas Jefferson University-aneurysmal subarachnoid hemorrhage.